Efficacy and safety of human chorionic gonadotropin combined with human menopausal gonadotropin and a gonadotropin-releasing hormone pump for male adolescents with congenital hypogonadotropic hypogonadism

Ying Liu, Xiao-Ya Ren, Ya-Guang Peng, Shao-Ke Chen, Xin-Ran Cheng, Miao Qin, Xiao-Ling Wang, Yan-Ning Song, Li-Jun Fan, Chun-Xiu Gong, Ying Liu, Xiao-Ya Ren, Ya-Guang Peng, Shao-Ke Chen, Xin-Ran Cheng, Miao Qin, Xiao-Ling Wang, Yan-Ning Song, Li-Jun Fan, Chun-Xiu Gong

Abstract

Background: Compared to adult studies, studies which involve the treatment of pediatric congenital hypogonadotropic hypogonadism (CHH) are limited and no universal treatment regimen is available. The aim of this study was to evaluate the feasibility of human chorionic gonadotropin (hCG)/human menopausal gonadotropin (hMG) therapy for treating male adolescents with CHH.

Methods: Male adolescent CHH patients were treated with hCG/hMG (n = 20) or a gonadotropin-releasing hormone (GnRH) pump (n = 21). The treatment was divided into a study phase (0-3 months) and a follow-up phase (3-12 months). The testicular volume (TV), penile length (PL), penis diameter (PD), and sex hormone levels were compared between the two groups. The TV and other indicators between the groups were analyzed using a t-test (equal variance) or a rank sum test (unequal variance).

Results: Before treatment, there was no statistical difference between the two groups in terms of the biochemistry, hormones, and other demographic indicators. After 3 months of treatment, the TV of the hCG/hMG and GnRH groups increased to 5.1 ± 2.3 mL and 4.1 ± 1.8 mL, respectively; however, the difference was not statistically significant (P > 0.05, t = 1.394). The PL reached 6.9 ± 1.8 cm and 5.1 ± 1.6 cm (P < 0.05, t = 3.083), the PD reached 2.4 ± 0.5 cm and 2.0 ± 0.6 cm (P < 0.05, t = 2.224), respectively, in the two groups. At the end of 6 months of treatment, biomarkers were in normal range in the two groups. Compared with the GnRH group, the testosterone (T) level and growth of PL and PD were significantly greater in the hCG/hMG group (all P < 0.05). While the TV of both groups increased, the difference was not statistically significant (P > 0.05, t = 0.314). After 9 to 12 months of treatment, the T level was higher in the hCG/hMG group. Other parameters did not exhibit a statistical difference.

Conclusions: The hCG/hMG regimen is feasible and effective for treating male adolescents with CHH. The initial 3 months of treatment may be a window to optimally observe the strongest effects of therapy. Furthermore, results from the extended time-period showed positive outcomes at the 1-year mark; however, the long-term effectiveness, strengths, and weaknesses of the hCG/hMG regimen require further research.

Trial registration: ClinicalTrials.gov, NCT02880280; https://ichgcp.net/clinical-trials-registry/NCT02880280.

Conflict of interest statement

None.

Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

Figures

Figure 1
Figure 1
Alteration of TV during 0 to 12 months of treatment. The TV of hCG/hMG and GnRH patients at various time intervals (months) after treatment onset. Bars represent mean ± standard deviation. The P value of the comparison at each time point is displayed at the top of the corresponding pairs of bars. GnRH: Gonadotropin-releasing hormone; H: Height; hCG: Human chorionic gonadotropin; hMG: Human menopausal gonadotropin; TV: Testicular volume.

References

    1. Boehm U, Bouloux P-M, Dattani MT, de Roux N, Dodé C, Dunkel L, et al. . Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism – pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2015; 11:547–564. doi: 10.1038/nrendo.2015.112.
    1. Bianco SDC, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol 2009; 5:569–576. doi: 10.1038/nrendo.2009.177.
    1. Jacques Y, Cheng X, Papadakis GE, Acierno JS, Maione L, Hietamäki J, et al. . Clinical management of congenital hypogonadotropic hypogonadism. Endocr Rev 2019; 40:669–710. doi: 10.1210/er.2018-00116.
    1. Gong C, Liu Y, Qin M, Wu D, Wang X. Pulsatile GnRH Is superior to hCG in therapeutic efficacy in adolescent boys with hypogonadotropic hypogonadodism. J Clin Endocrinol Metab 2015; 100:2793–2799. doi: 10.1210/jc.2015-1343.
    1. Department of Endocrinology, Chinese Medical Association, Department of Gonadology. Expert consensus on the diagnosis and treatment of idiopathic hypogonadotropin hypogonadism (in Chinese). Chin J Intern Med 2015; 54:739–744. doi: 10.3760/cma.j.issn.0578-1426.2015.08.021.
    1. Gong CX, Li LL. Procedure of diagnosis and treatment for disorders of sex development: based on the abundant clinical experiences and more than 400 cases of 46,XY disorders of sex development. Chin J Appl Clin Pediatr 2017; 32:1521–1525. doi: 10.3760/cma.j.issn.2095-428X.2017.20.001.
    1. Papadimitriou DT, Chrysis D, Nyktari G, Zoupanos G, Liakou E, Papadimitriou A, et al. . Replacement of male mini-puberty. J Endocr Soc 2019; 3:1275–1282. doi: 10.1210/js.2019-00083.
    1. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF, Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002; 87:4128–4136. doi: 10.1210/jc.2002-020518.
    1. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril 2009; 92:594–604. doi: 10.1016/j.fertnstert.2008.07.1720.
    1. Zacharin M, Sabin MA, Nair VV, Dagabdhao P. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. Fertil Steril 2012; 98:836–842. doi: 10.1016/j.fertnstert.2012.06.022.
    1. Rohayem J, Hauffa BP, Zacharin M, Kliesch S, Zitzmann M. the “German Adolescent Hypogonadotropic Hypogonadism Study Group”. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? – a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. Clin Endocrinol (Oxf) 2017; 86:75–87. doi: 10.1111/cen.13164.
    1. Sato N, Hasegawa T, Hasegawa Y, Arisaka O, Ozono K, Amemiya S, et al. . Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols. Clin Pediatr Endocrinol 2015; 24:37–49. doi: 10.1297/cpe.24.37.
    1. Schopohl J. Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males. Hum Reprod 1993; 8: Suppl 2: 175–179. doi: 10.1093/humrep/8.suppl_2.175.
    1. Liu L, Banks SM, Barnes KM, Sherins RJ. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1988; 67:1140–1145. doi: 10.1210/jcem-67-6-1140.
    1. Zhou XW, Wang N, Li YD. Evaluation of the age of the first spermatorrhea in China from 1980 to 2013 (in Chinese). China Public Health 2017; 33:1408–1413. doi: 10.11847/zgggws2017-33-09-29.
    1. Liang JP, Mai JC, Yang JW, Lin JL, Yao ZJ. Analysis of the age change trend of first-time spermatorrhea or menarche in Guangzhou from 1985 to 2014 (in Chinese). Chin J School Health 2016; 37:1670–1672. doi: 10.16835/j.cnki.1000-9817.2016.11.022.
    1. Gong C. Response to the Letter by Raivio T. et al. J Clin Endocrinol Metab 2015; 100:L75.doi: 10.1210/jc.2015-3030.
    1. Cortes D, Müller J, Skakkebæk NE. Proliferation of Sertoli cells during development of the human testis assessed by stereological methods. Int J Androl 1987; 10:589–596. doi: 10.1111/j.1365-2605.1987.tb00358.x.
    1. Ramaswamy S, Plant TM, Marshall GR. Pulsatile stimulation with recombinant single chain human luteinizing hormone elicits precocious sertoli cell proliferation in the juvenile male rhesus monkey (Macaca mulatta). Biol Reprod 2000; 63:82–88. doi: 10.1095/biolreprod63.1.82.
    1. Johnson L, Zane RS, Petty CS, Neaves WB. Quantification of the human sertoli cell population: Its distribution, relation to germ cell numbers, and age-related decline. Biol Reprod 1984; 31:785–795. doi: 10.1095/biolreprod31.4.785.
    1. Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ. Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Hum Reprod 2002; 17:625–633. doi: 10.1093/humrep/17.3.625.
    1. Raivio T, Wikstrom AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol 2007; 156:105–111. doi: 10.1530/eje.1.02315.
    1. Peking Union Medical College Hospital, Liu ZX. Identification of genetic pathology for patients with 46,XY disorders of sex development and efficacy and outcome predictors of gonadotropin-induced spermatogenesis for male patients with congenital hypogonadotropic hypogonadism. 2016.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever